New natural products of interest under development at the National Cancer Institute.
Fourteen new agents of natural products origin which are under development as antitumor agents at the National Cancer Institute are discussed with reference to their sources, structures, antitumor activity, current status, and future prospects as clinically effective agents.
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects / Q000494:pharmacology*; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects / Q000494:pharmacology*; D003609:Dactinomycin / Q000494:pharmacology; D004224:Diterpenes / Q000494:pharmacology; D004353:Drug Evaluation, Preclinical; D005900:Glaucarubin / Q000031:analogs & derivatives / Q000494:pharmacology; D005998:Glycine / Q000031:analogs & derivatives / Q000494:pharmacology; D006248:Harringtonines / Q000494:pharmacology; D006801:Humans; D007555:Isoxazoles / Q000494:pharmacology; D008453:Maytansine / Q000494:pharmacology; D009279:Naphthacenes / Q000494:pharmacology; D009316:National Institutes of Health (U.S.); D013729:Terpenes / Q000494:pharmacology; D014255:Trichothecenes / Q000494:pharmacology; D014481:United States
D000903:Antibiotics, Antineoplastic; D000972:Antineoplastic Agents, Phytogenic; D004224:Diterpenes; D006248:Harringtonines; D007555:Isoxazoles; D009279:Naphthacenes; D013729:Terpenes; D014255:Trichothecenes; D008453:Maytansine; D003609:Dactinomycin; D005900:Glaucarubin; D005998:Glycine